Search
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigationalLisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigationalZiftomenib is a potent and highly selective menin inhibitor. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory
Synonyms: (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile, (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1Hindole-2-carbonitrileViper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
Asapiprant
go.drugbank.com/drugs/DB20492InvestigationalAsapiprant has a monoisotopic molecular weight of 501.16 Da. … Asapiprant is a small molecule drug.
Alofanib
go.drugbank.com/drugs/DB20918InvestigationalAlofanib has a monoisotopic molecular weight of 413.07 Da. … Alofanib is a small molecule drug. The usage of the INN stem '-anib' in the name indicates that Alofanib is a angiogenesis inhibitor.
Urokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawn[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCabamiquine
go.drugbank.com/drugs/DB21477InvestigationalCabamiquine has a monoisotopic molecular weight of 462.24 Da. … Cabamiquine is a small molecule drug.
Fidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[L11575] Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. … [A190492] Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigationalThere are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and FDA that are approved to … [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.
Categories: Compounds used in a research, industrial, or household settingProducts: Pelgraz 6 mg solution for injection in a pre-filled syringe, NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML